Pharmaceutical

Gilead gains EC approval for metastatic breast cancer drug Trodelvy

Gilead Sciences has received approval from EC for Trodelvy, for pre-treated HR-positive, HER2-negative metastatic breast cancer.

Jul 29, 2023 - 20:00
Gilead gains EC approval for metastatic breast cancer drug Trodelvy
Gilead Sciences has received approval from EC for Trodelvy, for pre-treated HR-positive, HER2-negative metastatic breast cancer.
Read the original article

Tags:

Previous Article

InSilicoTrials and Axoltis to develop drugs for neurological disorders

Next Article

How did hiring in the Indian pharma industry perform in Q2 2023

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Signal: Novo Nordisk market cap higher than Danish GDP due to obesity drugs

Signal: Novo Nordisk market cap higher than Danish GDP ...

Sep 1, 2023

AltruBio secures $225m for immune checkpoint programme development

AltruBio secures $225m for immune checkpoint programme ...

May 23, 2024

Regeneron’s bispecific lymphoma antibody odronextamab wins FDA priority review

Regeneron’s bispecific lymphoma antibody odronextamab w...

Sep 29, 2023